Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 4:1:16.
doi: 10.3389/fonc.2011.00016. eCollection 2011.

Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease

Partow Kebriaei  1 , Simon Robinson
Affiliations

Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease

Partow Kebriaei et al. Front Oncol. .

Abstract

Mesenchymal stem cells (MSC) are a cellular component of the supportive microenvironment (stroma) found in the bone marrow, umbilical cord, placenta, and adipose tissues. In addition to providing cellular and extracellular cues to support the proliferation and differentiation of cells that comprise functional tissues, MSC also contribute to tissue repair and have immunomodulatory properties. Their ability to modulate immunologic reactions while themselves not provoking immunologic responses from alloreactive T-lymphocytes and/or other effector cells, make MSC a potentially ideal therapeutic agent with which to treat graft versus host disease (GvHD) following hematopoietic transplantation. Despite in vitro experiments confirming that MSC suppress mixed lymphocyte reactions (MLR) and in vivo evidence from mouse models that show evidence that MSC can ameliorate GvHD, clinical trials to date using MSC to treat GvHD have shown mixed results. Whether this is a consequence of suboptimal timing and dose of administered MSC remains to be clarified. It is clear that immunomodulatory potential of MSC as a cellular therapy for GvHD remains to be realized in the clinic.

Keywords: animal models; clinical trials; graft versus host disease; mesenchymal stem cell.

PubMed Disclaimer

References

    1. Aggarwal S., Pittenger M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815–1822 10.1182/blood-2004-04-1559 - DOI - PubMed
    1. Auletta J. J., Cooke K. R., Solchaga L. A., Deans R. J., vant Hof W. (2010). Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol. Blood Marrow Transplant. 16, 891–90610.1016/j.bbmt.2009.12.005 - DOI - PMC - PubMed
    1. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., Galun E., Rachmilewitz J. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214–2219 10.1182/blood-2004-07-2921 - DOI - PubMed
    1. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., Kluter H. (2009). Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27, 2331–2341 10.1002/stem.139 - DOI - PubMed
    1. Casiraghi F., Azzollini N., Cassis P., Imberti B., Morigi M., Cugini D., Cavinato R. A., Todeschini M., Solini S., Sonzogni A., Perico N., Remuzzi G., Noris M. (2008). Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181, 3933–3946 - PubMed

LinkOut - more resources